Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference
Jade Biosciences (NASDAQ: JBIO), a biotechnology company specializing in autoimmune disease therapies, has announced its participation in the upcoming Jefferies Global Healthcare Conference from June 3-5, 2025, in New York.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Jade Biosciences (NASDAQ: JBIO), a biotechnology company specializing in autoimmune disease therapies, has announced its participation in the upcoming Jefferies Global Healthcare Conference from June 3-5, 2025, in New York. CEO Tom Frohlich will deliver a company presentation on June 4 at 4:55-5:25 p.m. ET. The management team will also conduct investor meetings during the event.
The presentation will be accessible to investors and the public through the Investors and Media section of JadeBiosciences.com, with the recording remaining available for 90 days afterward.
Details
News Market Reaction – JBIO
The recorded move for JBIO in the trading session of this news was +0.35%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the Jefferies Global Healthcare Conference, June 3-5, 2025, in New York.
Tom Frohlich, Chief Executive Officer of Jade, will deliver a company presentation on Wednesday, June 4 at 4:55-5:25 p.m. ET. Members of the management team will also host investor meetings during the conference.
Investors and the general public are invited to listen to the session by visiting the Investors and Media page on JadeBiosciences.com. An archived edition will be available following its conclusion for 90 days.
About Jade Biosciences, Inc.
Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead candidate, JADE-001, targets the cytokine APRIL for immunoglobulin A nephropathy, with initiation of a first-in-human clinical trial expected in the second half of 2025. Jade’s pipeline also includes two undisclosed antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.
Jade Biosciences Contacts
Media Contact
Priyanka Shah
Media@JadeBiosciences.com
908-447-6134
Investor Contact
IR@JadeBiosciences.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.